Mode
Text Size
Log in / Sign up

Oncology

592 published articles · Updated continuously

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Narrative review explores interkingdom interactions in subgingival microbiome and periodontitis
Oncology Sys. Review
Narrative review explores interkingdom interactions in subgingival microbiome and periodontitis What if gum disease isn't just about bacteria?
A narrative review synthesizes evidence on host-pathogen interactions involving bacteria, fungi, viruses, and archaea in periodontitis. It d…
Gum disease isn't just about bacteria; fungi and viruses team up with them to make infections worse and damage tissue.
Meta-analysis finds geographical disparities in FIT-based colorectal cancer screening participation
Oncology Meta-analysis
Meta-analysis finds geographical disparities in FIT-based colorectal cancer screening participation Where you live may affect your chance of getting screened for colon cancer.
A systematic review and meta-analysis of 35 studies in average-risk adults aged 40-74 examined geographical disparities in FIT-based CRC scr…
Where you live changes your chances of taking a colon cancer stool test, but the test works equally well everywhere regardless of location.
Review proposes DC-NK metabolic checkpoint concept in viral asthma exacerbations
Oncology Sys. Review
Review proposes DC-NK metabolic checkpoint concept in viral asthma exacerbations Why do colds hit people with asthma so hard? A new idea points to exhausted immune cells.
A systematic review synthesizes murine and in vitro evidence proposing that dendritic cell-natural killer cell metabolic dysregulation contr…
Asthma colds trigger dangerous flares because stressed immune cells create an acidic environment that exhausts the virus-fighting cells need…
Review examines adoptive cellular therapies and immunoproteasome role in relapsed/refractory multiple myeloma
Oncology Sys. Review
Review examines adoptive cellular therapies and immunoproteasome role in relapsed/refractory multiple myeloma Review explores cellular therapies and immune system targeting for multiple myeloma
A systematic review discusses emerging evidence for adoptive cellular therapies (CAR T-cells, TCR-engineered T-cells) in relapsed/refractory…
Cellular therapies like CAR T-cells show promise for treating multiple myeloma, but severe side effects, high costs, and resistance limit th…
Case report describes diagnostic challenges in bilateral epithelioid sarcoma of the thigh
Oncology Sys. Review
Case report describes diagnostic challenges in bilateral epithelioid sarcoma of the thigh Imaging tests missed rare cancer in woman with thigh tumors, case report shows
A case report and literature review describes a 47-year-old woman with bilateral thigh masses where ultrasonography and MRI failed to provid…
Common scans missed a rare cancer in a woman with thigh tumors, proving that biopsies are vital when imaging results are unclear.
COVID-19 associated with increased lung cancer risk in current smokers; spike protein drives tumorigenesis in mice
Oncology Cohort
COVID-19 associated with increased lung cancer risk in current smokers; spike protein drives tumorigenesis in mice Study finds link between COVID-19 and higher lung cancer risk in current smokers
A retrospective cohort analysis of 166,807 current smokers found COVID-19 was associated with increased lung cancer risk (RR 1.22; HR 1.50).…
Current smokers with a history of COVID-19 face a higher risk of developing lung cancer, a link scientists traced to a specific virus protei…
Locoregional CAR T-cell delivery reduces severe adverse events in high-grade glioma patients
Oncology Meta-analysis
Locoregional CAR T-cell delivery reduces severe adverse events in high-grade glioma patients Could a new way to deliver brain cancer therapy make it safer and more effective?
A meta-analysis of 14 clinical trials involving 194 high-grade glioma patients found locoregional CAR T-cell delivery was associated with re…
Delivering brain cancer therapy directly to the tumor instead of through the bloodstream cuts severe side effects by more than 60% and shows…
Report examines HPV-associated cancer incidence in American Indian and Alaska Native populations
Oncology
Report examines HPV-associated cancer incidence in American Indian and Alaska Native populations Report examines HPV-related cancer rates in American Indian and Alaska Native communities
An observational report describes HPV-associated cancer incidence in American Indian and Alaska Native populations in the United States. Spe…
A new report tracks HPV-related cancer cases in American Indian and Alaska Native communities across the United States from 2013 to 2017.
CD8 PET imaging shows modest correlation with biopsy CD8 counts in solid tumor patients on immunotherapy
Oncology Phase II
CD8 PET imaging shows modest correlation with biopsy CD8 counts in solid tumor patients on immunotherapy New imaging method shows modest link to immune cell counts in solid tumors
A Phase II prospective multicenter study of 49 patients with solid tumors receiving immune checkpoint blockade found a modest correlation (c…
A new PET scan shows a modest link to immune cell counts inside solid tumors, with stronger results in kidney cancer patients.
Phase 3 trial of navitoclax plus ruxolitinib versus ruxolitinib alone in myelofibrosis posts results
Oncology Phase III
Phase 3 trial of navitoclax plus ruxolitinib versus ruxolitinib alone in myelofibrosis posts results Phase 3 trial tests navitoclax with ruxolitinib for myelofibrosis spleen volume
A phase 3 randomized controlled trial in 252 adults with myelofibrosis compared navitoclax plus ruxolitinib to ruxolitinib plus placebo. The…
A new drug combination aims to shrink painful enlarged spleens in myelofibrosis patients, but results from this large global trial are not y…
Modeling study predicts human pharmacokinetics for TAK-500, an anti-CCR2 antibody-drug conjugate
Oncology Phase I
Modeling study predicts human pharmacokinetics for TAK-500, an anti-CCR2 antibody-drug conjugate Early modeling study predicts how a new cancer drug candidate might behave in humans
A preclinical and clinical modeling study used cynomolgus monkey data and human parental antibody data to simulate human pharmacokinetics fo…
A computer model predicts that a new cancer drug stays in the body longer as the dose increases, helping scientists plan safe first-in-human…
FDA Approves Zynyz (retifanlimab-dlwr) for Metastatic Anal Canal Cancer and Merkel Cell Carcinoma
Oncology FDA Approval
FDA Approves Zynyz (retifanlimab-dlwr) for Metastatic Anal Canal Cancer and Merkel Cell Carcinoma FDA approves new drug Zynyz for two rare and aggressive types of cancer.
The FDA has approved Zynyz, a PD-1 blocking antibody, for two indications: first-line treatment of inoperable locally recurrent or metastati…
FDA approves new drug Zynyz to treat two rare and aggressive cancers: advanced anal cancer and Merkel cell carcinoma.